Navigation Links
Biocept, Inc. Announces CEO and Director Appointments
Date:10/6/2008

SAN DIEGO, Oct. 6 /PRNewswire/ -- Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced today the appointment of Stephen M. Coutts, Ph.D. as CEO, President and Director and the appointment of Edward A. Dennis, Ph.D., as Director. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. Janko.

"We are pleased to welcome Dr. Coutts, a highly regarded professional in our field, and believe he is a good fit with our development strategy," said Claire K.T. Reiss, Chairman of the Board. "In addition, we are honored to add Dr. Dennis to the Board and look forward to benefiting from his extensive experience and perspective. On behalf of the Biocept Board of Directors, I would also like to thank Mr. Janko for his contributions during the five years that he led Biocept," Ms. Reiss added.

"I am delighted to join Biocept at this critical time and look forward to continuing to develop and grow this exciting technology," said Dr. Coutts.

Dr. Coutts has 30 years of experience in the pharmaceutical and biotechnical industries. He was most recently Director of Pharmaceutical Development at Cypress Bioscience, Inc. and a principal at Alembic Biotech Consultants. He was previously President and COO at Triad Therapeutics, Inc. and spent 11 years as Executive Vice President for R&D at La Jolla Pharmaceutical. Dr. Coutts holds a BS in Chemistry from San Diego State University, a Ph.D. in Biochemistry from Harvard University and an MBA from New York University.

Dr. Dennis is Distinguished Professor of Chemistry and Biochemistry and of Pharmacology in the School of Medicine at the University of California at San Diego (UCSD). He is currently Editor-in-Chief of the Journal of Lipid Research and has been named a Fellow of the American Association for the Advancement of Sciences. Dr. Dennis serves on the Scientific Advisory Board and Board of Directors of several private and public companies. He received his BA from Yale University and a Ph.D. from Harvard University.

About Biocept

Biocept, an emerging biotechnology leader, engineers novel microfluidic devices that provide the foundation for a new class of diagnostic assays. Biocept is based in San Diego, California, a major center for academic and industrial life sciences research. Founded in 1997, the company is privately held and draws on a team rich in experience in life science. Its CLIA clinical laboratory is accredited by the College of American Pathologists and holds licenses in California and other states as required.


'/>"/>
SOURCE Biocept, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Glemser Announces New Labeling Solution: SPL for DCM Addresses New SPL Release 4 Requirements
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Connecticut Technology Council Announces UHY LLP Tech Top 40 Winners
4. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
5. SyntheMed Announces New Management Appointments
6. Alba Therapeutics Corporation Announces Promotions
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. 23andMe Announces Breast Cancer Initiative
9. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
10. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
11. Synthetech Announces New Director of Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):